Transperineal Laser Ablation for Low- and Intermediate Risk Prostate Cancer: a Single Cohort Analysis
Launched by SAN CARLO DI NANCY HOSPITAL · Oct 16, 2022
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called transperineal laser ablation for men with low- and intermediate-risk prostate cancer. The goal is to see how effective this treatment is in controlling the cancer over time and how it affects the patients’ quality of life and everyday function. Participants in the trial will undergo a special type of laser therapy, and then they will have imaging and tests done at 3 and 12 months to check on their cancer and overall health.
To be eligible for this trial, men must be diagnosed with low- or intermediate-risk prostate cancer, specifically classified as ISUP 1-2. Those with other types of cancer, issues that prevent them from having an MRI, or multiple cancer spots in the prostate will not be included. Participants can expect regular follow-ups to monitor their health and well-being after the treatment. This trial is currently recruiting participants, and it aims to provide valuable insights into this new treatment option for prostate cancer.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with low- and intermediate risk prostate cancer classified as International Society for Urological Pathology, ISUP 1-2.
- Exclusion Criteria:
- • patients diagnosed with urothelial cancer
- • contraindications for MRI
- • Multifocal prostate cancer
About San Carlo Di Nancy Hospital
San Carlo di Nancy Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. Located in Rome, Italy, the hospital is renowned for its commitment to clinical excellence and innovation. With a multidisciplinary approach, San Carlo di Nancy Hospital conducts a variety of clinical trials across diverse therapeutic areas, aiming to enhance understanding of diseases and develop new treatment modalities. The hospital's collaboration with academic institutions and industry partners underscores its role as a pivotal player in the advancement of medical science, ensuring that cutting-edge treatments are accessible to patients in a timely manner.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roma, Rm, Italy
Patients applied
Trial Officials
Pierluigi Bove, MD
Principal Investigator
San Carlo di Nancy Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials